Notably, all platforms identified putative pathogenic mutations in half of the discovery families tested, either in high-risk genes (such as MSH2), in moderate-risk genes (CHEK2, ATM, BARD1) or in genes related to hereditary cancer susceptibility without a well-known associated risk (FANCM, FANCL, ERCC3). This evidence concerns the gene ERCC3 and hereditary cancer.